CooperCompanies Announces Q2 2024 Financial Results and Raises Full-Year Guidance

SAN RAMON, Calif.—CooperCompanies (Nasdaq: COO), a global medical device company, has announced financial results for its fiscal second quarter ended April 30, 2024. CooperCompanies reported revenues under two major segments—CooperVision (CVI) and CooperSurgical (CSI). The company reported that overall revenue increased 7 percent year-over-year to $942.6 million. CVI revenue was up 8 percent to $635.9 million and CSI revenue grew 6 percent to $306.7 million, according to the announcement. "I'm pleased to report record quarterly revenues and great operational progress throughout the organization," said Al White, Cooper's president and CEO.

Summer Celebrations Prompt Renewed Call for Improved Fireworks Safety

With the summer months approaching, there are lots of reasons to celebrate, and one of the most popular ways to do so is with fireworks. Before lighting up the night sky, however, it is important to take the right precautions to avoid injuries, especially injuries to the eyes. According to the Consumer Product Safety Commission’s 2022 Fireworks Annual Report, there were more than 10,000 injuries and 11 deaths that year resulting from firework injuries. Today, VMAIL Weekend takes a look at why fireworks are so dangerous and how ECPs can educate their patients about staying safe this summer season.

KeraLink International Names Michelle Bockman as New President and CEO

BALTIMORE—KeraLink International (KLI), a non-profit organization that provides solutions and technologies to underserved populations suffering from corneal blindness in low- and middle-income countries, has appointed Michelle Bockman as president and chief executive officer, according to an announcement from the company. Bockman will shape the organization’s future direction and lead her team in forging strategic partnerships with generous donors and impact investors, KLI told VMAIL. The company said these investors are committed to restoring sight to the more than 12.7 million people with corneal blindness and to making significant advances in the prevention and early treatment of corneal injury and disease.

Merck to Acquire EyeBio for Up to $3 Billion

RAHWAY, N.J. and NEW YORK—Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio. Under the terms of the agreement, Merck will acquire all outstanding shares of EyeBio for up to $3 billion, including an upfront payment of $1.3 billion in cash and a further potential $1.7 billion in developmental, regulatory and commercial milestone payments, the announcement stated. The acquisition has been unanimously approved by the EyeBio board of directors.

CooperCompanies Publishes 2023 Environmental, Social, and Governance Report

SAN RAMON, Calif.—CooperCompanies (Nasdaq: COO) has released its 2023 Environmental, Social, and Governance (ESG) report, which describes the company’s “progress on enhancing the health and wellness of people around the world while protecting the planet and serving its communities.” The company notes in the report that it made significant investments in learning and development programs for global employees, maintained its commitment to protect the planet, and continued making its health care solutions more accessible in underserved communities.